ARNAS Civico Di Cristina Benfratelli

At ARNAS Civico Di Cristina Benfratelli, clinical trials in multiple sclerosis, generalized myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy focus on improving symptom control, slowing disease activity, and testing new treatment options for immune-related nervous system disorders.

• Relapsing and progressive forms of multiple sclerosis
• Myasthenia gravis and daily function outcomes
• Inflammatory neuropathies such as CIDP

These studies aim to evaluate whether newer therapies can better reduce disability and preserve quality of life in patients with chronic neurologic disease.

The site has a strong research profile in acute lymphoblastic leukemia, lymphoblastic lymphoma, neuroblastoma, rhabdomyosarcoma, and other childhood cancers, with trials designed to improve survival and reduce relapse risk.

• Acute lymphoblastic leukemia in children, adolescents, and relapsed disease
• Lymphoblastic lymphoma and related blood cancers
• Neuroblastoma, rhabdomyosarcoma, and osteosarcoma

Research at this hospital includes testing more effective treatment combinations and refining care for high-risk or relapsed cancers.

Clinical trials in cardiovascular disease, heart failure, hypertension, and type 2 diabetes are exploring ways to lower major cardiac risks and improve long-term disease control.

• Heart failure and prevention of worsening disease
• Atherosclerotic cardiovascular disease and systemic inflammation
• Type 2 diabetes with high cardiovascular risk

These studies are aimed at finding better strategies to prevent complications and support patients living with complex cardiometabolic conditions.

Research in solid tumors at ARNAS Civico Di Cristina Benfratelli includes trials in colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, and urothelial cancer, often with a focus on targeted and personalized treatment approaches.

• Metastatic colorectal cancer and molecularly selected subgroups
• Prostate cancer, including advanced and high-risk disease
• Ovarian, pancreatic, and urothelial cancers

The main goal is to evaluate whether tailored therapies can improve response, delay progression, and offer better outcomes than standard treatment alone.

Trials in juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, recurrent pericarditis, and other immune-mediated disorders are studying how to better control inflammation and prevent flares.

• Juvenile idiopathic arthritis and treatment strategies in children
• Systemic juvenile idiopathic arthritis and targeted therapy
• Recurrent pericarditis and steroid-sparing approaches

These studies seek safer and more effective options for patients who do not respond well to standard anti-inflammatory care.

The site also supports trials in IgA nephropathy, endometriosis, digestive system diseases, and other conditions, showing a broad interest in both chronic disease management and symptom relief.

• IgA nephropathy and kidney protection
• Endometriosis and pain-related outcomes
• Metabolic and immune-mediated conditions with unmet treatment needs

These studies are designed to improve diagnosis, reduce disease burden, and test therapies that may offer better control with fewer side effects.